Last reviewed · How we verify
Nicotine delivered via an e-cigarette
Nicotine acts as a nicotinic acetylcholine receptor agonist, binding to and activating these receptors in the central and peripheral nervous system.
Nicotine acts as a nicotinic acetylcholine receptor agonist, binding to and activating these receptors in the central and peripheral nervous system. Used for Smoking cessation aid, Reduction of cigarette consumption in smokers unwilling or unable to quit.
At a glance
| Generic name | Nicotine delivered via an e-cigarette |
|---|---|
| Also known as | Brand name: UpOx |
| Sponsor | University of Auckland, New Zealand |
| Drug class | Nicotinic acetylcholine receptor agonist |
| Target | Nicotinic acetylcholine receptors (nAChR) |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | Phase 3 |
Mechanism of action
Nicotine crosses the blood-brain barrier and binds to nicotinic acetylcholine receptors, particularly α4β2 subtypes, leading to dopamine release and stimulation of the reward pathway. This mechanism underlies both its addictive properties and potential therapeutic effects on cognition, attention, and mood. When delivered via e-cigarette, nicotine is inhaled and rapidly absorbed through the lungs, providing quick onset of action similar to combustible cigarettes but without tobacco combustion byproducts.
Approved indications
- Smoking cessation aid
- Reduction of cigarette consumption in smokers unwilling or unable to quit
Common side effects
- Throat irritation
- Cough
- Nausea
- Dizziness
- Headache
- Nicotine dependence
Key clinical trials
- Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS (NA)
- Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion) (PHASE3)
- Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: